NovaBridge Biosciences

NASDAQ:NBPHealthcare · Biotechnology

Mkt Cap$164.22M

Float64.44M

Shares O/S115.65M

Inst Own21.3%

SI5.1%

Dilution

+6.77%$1.42

AH Close$1.42+0.00%vs close

Mkt Cap$164.22M

Float64.44M

O/S115.65M

Inst Own21.3%

SI5.1%

Dilution

NASDAQ:NBP$1.42+6.77%

MCap$164.22M

Float64.44M

O/S115.65M

SI5.1%

Inst Own21.3%

Dilution

Historical Data

Date	Open	High	Low	Close	Volume

Key Metrics

Market Cap$164.22M

Enterprise Value--

P/E Ratio--

Est. Net Cash/Share--

Institutional Ownership21.34%

based on 115.65M shares outstanding

SectorHealthcare

IndustryBiotechnology

ExchangeNASDAQ

Country

IPO DateJan 17, 2020

Shares Outstanding115.65M

Float64.44M

Company Overview

NovaBridge Biosciences, a biotechnology firm, primarily focuses on pioneering immuno-oncology treatments for cancer patients within the United States.

Its development pipeline features several significant drug candidates: givastomig, a bispecific antibody currently in Phase 1b clinical trials for gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, another bispecific antibody, which is undergoing Phase 1 clinical evaluation for solid tumors.

The company maintains a strategic licensing agreement with Ferring International Center SA, encompassing the research, development, manufacturing, import, use, and commercialization rights for FE301, an interleukin-6 inhibitor.

Additionally, NovaBridge Biosciences has established collaborations with Bristol Myers Squibb for givastomig's advancement, ABL Bio, Inc. for both givastomig and ragistomig, and TJ Bio for uliledlimab. Founded in 2014 and headquartered in Rockville, Maryland, the entity was formerly named I-Mab, with its transition to NovaBridge Biosciences slated for October 2025.

Leadership

Cong Xu

Senior VP and Head of R&D Center of Excellence

Liwei Lin

General Counsel & Board Secretary

Mark Hagler

President & Chief Commercial Officer

Ming Lei

Chief Financial Officer

Employees

Country

Sector

Healthcare

Website

i-mabbiopharma.com

Analyst Coverage

ConsensusBuy

Price Target

No price targets available

Ratings Distribution

BUY

HOLD

SELL

TOTAL11

Insider Trading

Insider	Title	Type	Shares	Value	Date
Woo Ian Ying	Director	Option Exercise	13.3K	--	Oct 15, 2026
Woo Ian Ying	Director	Option Exercise	5.8K	--	Oct 15, 2026
Dennis Phillip Andrew	Chief Medical Officer	Sale	8.2K	$5.8K	Sep 18, 2026
Dennis Phillip Andrew	Chief Medical Officer	Option Exercise	10.3K	--	Sep 17, 2026
Dennis Phillip Andrew	Chief Medical Officer	Option Exercise	23.7K	--	Sep 17, 2026
Cao Sean Wuxiong	Chief Bus. Development Officer	Sale	108.0K	$79.9K	Sep 9, 2026

Shareholders

21.3%

Institutional

(49)

1.7%

Insiderⓘ

(9)

7.1%

5%+ Owners

(2)

of which 7.1% rests on schedules older than 24 months (2 holders)

69.9%

Unattributed (incl. retail)ⓘ

Institutional21.3%

Insider1.7%

5%+ Beneficial7.1%

Unattributed (incl. retail)69.9%

Top Shareholders

Name	Shares	%	Source
Everest Medicines Limited · may incl. warrants· filed Aug 2025	42.5M	16.1% as filed	13D
CBC Investment I-Mab Limited · may incl. warrants· filed Feb 2026	11.8M	4.4% as filed	13D
Jingwu Zhang Zang · may incl. warrants· filed Feb 2024	10.5M	5.6% as filed	13G
T INVESTMENT LIMITED · may incl. warrants· stale · filed Dec 2023	8.2M	7.1%	13D
HHLR ADVISORS, LTD.	6.0M	5.2%	13F
MORGAN STANLEY	3.7M	3.2%	13F
AIHC Capital Management Ltd	2.9M	2.5%	13F
Siren, L.L.C.	2.0M	1.7%	13F
MARSHALL WACE, LLP	1.2M	1.1%	13F
Candriam S.C.A.	1.1M	1.0%	13F